代谢组学在视网膜健康与疾病研究中的应用
本文综述代谢组学(对体液中<1.5 kDa小分子的定性与定量评估)在视网膜疾病研究中的应用,系统总结开展代谢组学研究所需的工具与知识、严谨研究设计与数据分析的关键统计方法、组织与生物体液收集处理方案,并批判性分析糖尿病视网膜病变和年龄相关性黄斑变性在动物模型与人类临床中的近期研究,指出未来应用机会以改善玻璃体视网膜疾病的评估与患者护理。
要点
- 代谢组学检测体液中小于1.5 kDa的代谢物,可反映基因转录翻译下游及环境暴露交互,与表型密切相关。
- 视网膜疾病代谢组学应用仍有限,本文汇总研究设计、统计分析、样本收集处理的最佳方案。
- 综述批判性分析糖尿病视网膜病变与年龄相关性黄斑变性在动物模型和人类临床中的代谢组学研究。
核心结论
- 代谢组学是识别疾病生物标志物并理解病理生理与机制的有力工具,具临床转化潜力。
- 视网膜疾病代谢组学应用有限,需规范研究设计、统计分析与样本处理以推进临床转化。
研究设计与样本
- 综述类文章,综合总结代谢组学研究的工具与知识、严谨研究设计与数据分析的统计方法、组织与生物体液收集处理方案。
- 批判性分析糖尿病视网膜病变和年龄相关性黄斑变性在动物模型与人类临床中的近期代谢组学研究。
主要发现
- 代谢物是基因转录翻译及环境暴露交互的下游,与表型尤其多因素疾病密切相关。
- 过去十年代谢组学越来越多用于疾病生物标志物识别,被认作具临床转化潜力的强大工具。
- 代谢组及相关通路有助于理解疾病病理生理与机制。
- 视网膜疾病是致盲主要原因,但代谢组学在该领域的应用仍有限。
临床怎么用
- 开展视网膜疾病代谢组学研究应参考本文汇总的研究设计、统计分析与组织/生物体液收集处理最佳方案。
- 代谢组学可用于改进玻璃体视网膜疾病的机制理解、患者评估与护理。
局限性
- 原文指出视网膜疾病代谢组学应用有限,且存在组织与生物体液收集处理信息未满足的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolomics is the qualitative and quantitative assessment of the metabolites (small molecules < 1.5 kDa) in body fluids. The metabolites are the downstream of the genetic transcription and translation processes and also downstream of the interactions with environmental exposures; thus, they are thought to closely relate to the phenotype, especially for multifactorial diseases. In the last decade, metabolomics has been increasingly used to identify biomarkers in disease, and it is currently recognized as a very powerful tool with great potential for clinical translation. The metabolome and the associated pathways also help improve our understanding of the pathophysiology and mechanisms of disease. While there has been increasing interest and research in metabolomics of the eye, the application of metabolomics to retinal diseases has been limited, even though these are leading causes of blindness. In this manuscript, we perform a comprehensive summary of the tools and knowledge required to perform a metabolomics study, and we highlight essential statistical methods for rigorous study design and data analysis. We review available protocols, summarize the best approaches, and address the current unmet need for information on collection and processing of tissues and biofluids that can be used for metabolomics of retinal diseases. Additionally, we critically analyze recent work in this field, both in animal models and in human clinical disease, including diabetic retinopathy and age-related macular degeneration. Finally, we identify opportunities for future research applying metabolomics to improve our current assessment and understanding of mechanisms of vitreoretinal diseases, and to hence improve patient assessment and care.
引用
- Laíns I, Gantner M, Murinello S, et al. Metabolomics in the study of retinal health and disease. Prog Retin Eye Res. 2018. PMID: 30423446. doi:10.1016/j.preteyeres.2018.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。